Can-Fite BioPharma Ltd. (CANF) stock
CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.42−0.07 (-4.70%)
Close on Nov 13, 2026Market cap $1.86MP/E –Yield –
Can-Fite BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $6.69M, up 16.3% from the year before. Over ten years it grew 5.5% a year on average. The highest annual figure on record is $11.95M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.69M | +16.3% |
| FY2024 | Dec 31, 2024 | $5.76M | -3.8% |
| FY2023 | Dec 31, 2023 | $5.98M | -22.9% |
| FY2022 | Dec 31, 2022 | $7.76M | -21.2% |
| FY2021 | Dec 31, 2021 | $9.85M | -17.6% |
| FY2020 | Dec 31, 2020 | $11.95M | +8.9% |
| FY2019 | Dec 31, 2019 | $10.98M | +80.7% |
| FY2018 | Dec 31, 2018 | $6.08M | +19.0% |
| FY2017 | Dec 31, 2017 | $5.11M | -16.5% |
| FY2016 | Dec 31, 2016 | $6.12M | +56.6% |
| FY2015 | Dec 31, 2015 | $3.90M | – |
See a number that looks wrong?